Larimar Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +60.9% | -30.4% | -19.8% | +15.4% | -95.7% | +1,912.8% | -24.9% | +60.7% | -24.1% | +108.7% | -27.2% | |
| – | +60.5% | -30.4% | -19.8% | +15.6% | -96.1% | +1,962.1% | -26.3% | +67.2% | -25.3% | +116.6% | -27.3% | |
| – | -38.7% | -9.1% | +26.0% | +21.0% | -98.0% | +6,654.0% | +2.9% | -61.7% | -0.3% | +24.2% | +157.1% | |
| – | +60.3% | -30.2% | -21.0% | +15.7% | -99.1% | +9,081.2% | -24.3% | +68.9% | -26.7% | +111.4% | -25.4% | |
| – | – | -73.8% | +172.6% | +62.4% | -89.7% | -79.7% | +550.0% | – | – | +217.5% | -29.1% | |
| – | – | – | – | – | – | -101.0% | – | – | – | – | – | |
| – | – | -26.7% | -20.1% | -49.1% | +34.2% | +1,278.4% | -10.5% | -81.3% | – | – | – | |
| – | +52.9% | -50.5% | +175.9% | +4.4% | -79.3% | +154.4% | -4.9% | +8.8% | -8.3% | +99.9% | +138.5% | |
| – | +139.7% | -40.2% | -26.3% | +82.4% | -55.7% | +52.5% | -1.6% | +21.0% | -11.2% | +156.2% | +166.0% | |
| – | +112.6% | +22.2% | – | – | -98.2% | +430.9% | +15.3% | +2.9% | +37.0% | +26.6% | +4.2% | |
| – | +219.2% | -65.7% | +17.4% | -69.9% | +289.3% | -25.6% | -37.0% | +1.6% | -23.9% | +88.9% | +115.2% | |
| – | – | – | – | -24.1% | -44.3% | – | – | – | – | – | – | |
| – | +61.9% | -28.0% | -35.7% | +19.2% | -100.7% | – | -28.2% | +72.2% | -26.3% | +110.2% | -54.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -7.7% | +2.0% | +0.5% | +17.5% | +16.0% | +281.5% | +44.4% | +50.1% | +70.4% | +39.5% | +19.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.